ATAI Life Sciences BV

Company Profile

ATAI Life Sciences BV had its IPO on 2008-01-29 under the ticker symbol ATAI.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. ATAI Life Sciences BV has a staff strength of 0 employees.

Stock update

Shares of ATAI Life Sciences BV opened at $3.3 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $3.09 - $3.43, and closed at $3.14.

This is a -7.1% slip from the previous day's closing price.

A total volume of 919,885 shares were traded at the close of the day’s session.

In the last one week, shares of ATAI Life Sciences BV have increased by +4.67%.

ATAI Life Sciences BV's Key Ratios

ATAI Life Sciences BV has a market cap of $0.521 billion, indicating a price to book ratio of 1.597 and a price to sales ratio of 782.05.

In the last 12-months ATAI Life Sciences BV’s revenue was $0.001 billion with a gross profit of $0.020 billion and an EBITDA of $-0.140 billion. The EBITDA ratio measures ATAI Life Sciences BV's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, ATAI Life Sciences BV’s operating margin was -21086% while its return on assets stood at -20.5% with a return of equity of -49.7%.

In Q2, ATAI Life Sciences BV’s quarterly earnings growth was a negative -96.8% while revenue growth was a positive 0%.

ATAI Life Sciences BV’s PE and PEG Ratio

Forward PE

-

Trailing PE

-

PEG

None

Its diluted EPS in the last 12-months stands at $-1.399 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ATAI Life Sciences BV’s profitability.

ATAI Life Sciences BV stock is trading at a EV to sales ratio of 278.92 and a EV to EBITDA ratio of -1.324. Its price to sales ratio in the trailing 12-months stood at 782.05.

ATAI Life Sciences BV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

ATAI Life Sciences BV ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

ATAI Life Sciences BV ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

ATAI Life Sciences BV’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, ATAI Life Sciences BV's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, ATAI Life Sciences BV paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$3.14

52-Week High

$17.75

52-Week Low

$2.6

Analyst Target Price

$23.47

ATAI Life Sciences BV stock is currently trading at $3.14 per share. It touched a 52-week high of $17.75 and a 52-week low of $17.75. Analysts tracking the stock have a 12-month average target price of $23.47.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.